EpiPen Alternative Available in February Will Be Free to Many

Tori Marsh
Tori Marsh, MPH, is on the Research Team at GoodRx, and is the resident expert on drug pricing and savings.
Posted on

You might be tired of hearing about the EpiPen pricing controversy after the past couple of months. In 2016, it felt like the the life-saving epinephrine auto-injector would never be affordable, as even generic epinephrine was priced around $300.

However, the new year has brought good news for auto-injector patients. As you may have heard, CVS announced last week that they would be offering the an EpiPen alternative for $109.99, and this week we have even more good news. According to the manufacturer Kaleo, an Epipen alternative, Auvi-Q, will be hitting pharmacies on February 14th. And the best part? Kaleo is making Auvi-Q free for many consumers.

What is Auvi-Q?

Just like EpiPen, Auvi-q is an epinephrine auto-injector used to counteract anaphylaxis, however there are some differences. For one, at the size of a credit card, the Auvi-Q is smaller than the EpiPen. The Auvi-Q also has a voice prompt system that guide patients through the epinephrine delivery process. You can read more about Auvi-Q here.

How much will Auvi-Q cost?

Auvi-Q has been listed at $4,500 for two auto-injectors. We know, this isn’t cheap. However, Kaleo has made it their mission to make Auvi-Q affordable and is guaranteeing a cash price of $360. Even better though—there are ways for most consumers to get Auvi-Q for free!

How can I qualify to get Auvi-Q for free?

Kaleo has created the Auvi-Q Affordability Program with the mission to make the auto-injector affordable for everyone. Under this program, there are two ways you can get the auto-injector for free:

  1. Anyone with insurance, including those with high-deducible plans, will able to get Auvi-Q with no out-of-pocket cost.
  2. Anyone without insurance can also get Auvi-Q free of charge if your household has an annual income of $100,000 or less.

Too good to be true? We don’t think so. In a recent press release, Kaleo Chief Executive Spencer Williamson mentioned that he is “confident the model provides access and affordability, and that it is a sustainable model.”

It seems like things with the epinephrine auto-injector are finally looking up! Stay tuned, and we will let you know when Auvi-Q is released.

Drugs featured in this story

Filed under